Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline

Kyung Jin Min, Sang Hoon Kwon, Kidong Kim, Sunghoon Kim, Hyun Jung Kim, Seok Ju Seong, Yong Jung Song, Keun Ho Lee, Shin Wha Lee, Jeong Won Lee, Suk Joon Chang, Woong Ju, Young Tak Kim, Jae Kwan Lee

Research output: Contribution to journalReview article

Abstract

In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

Original languageEnglish
Pages (from-to)e31
JournalJournal of gynecologic oncology
Volume30
Issue number2
DOIs
Publication statusPublished - 2019 Mar 1

Keywords

  • Female
  • Male
  • Papillomavirus Vaccines
  • Practice Guidelines

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline'. Together they form a unique fingerprint.

  • Cite this

    Min, K. J., Kwon, S. H., Kim, K., Kim, S., Kim, H. J., Seong, S. J., Song, Y. J., Lee, K. H., Lee, S. W., Lee, J. W., Chang, S. J., Ju, W., Kim, Y. T., & Lee, J. K. (2019). Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline. Journal of gynecologic oncology, 30(2), e31. https://doi.org/10.3802/jgo.2019.30.e31